☆ 4.5 Article

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

BLOOD CANCER JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

Follicular lymphoma: The long and winding road leading to your cure?

Max J. Gordon et al.

Summary: This article reviews the development and treatment of follicular lymphoma, including the molecular concepts and classification, chemotherapy and monoclonal antibodies targeting CD20. It also highlights the research progress in understanding the pathophysiology of follicular lymphoma and developing targeted therapies over the past decade, as well as new immunotherapeutic strategies for B-cell lymphomas, particularly advanced stage patients. These studies bring hope for the treatment of follicular lymphoma.

BLOOD REVIEWS (2023)

添加到收藏夹

Review Hematology

Time for an individualized approach to first-line management of follicular lymphoma

Guillaume Cartron et al.

Summary: Follicular lymphoma is a heterogeneous B-cell lymphoma with varying presentations and progressions. While most patients have a chronic, relapsing indolent disease with potential survival exceeding 20 years, a significant minority (approximately 20%) experience early progression or histological transformation after treatment, leading to a loss of indolent behavior. This review explores the development of prognostic indices, staging, and therapies for follicular lymphoma, aiming to guide the multidisciplinary team in determining an individualized approach to first-line therapy. A meticulous patient- and disease-specific approach is crucial in achieving optimal disease response and survival while minimizing therapeutic toxicity.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo et al.

Summary: Observational studies and stand-alone trials have shown that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy have poor outcomes. This pooled analysis of clinical trials validates POD24 as a robust indicator of poor FL survival and identifies clinical predictors of early death and progression, which can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.

BLOOD (2022)

添加到收藏夹

Article Biology

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Claire M. Patterson et al.

Summary: The study presents the design and development of AZD0466, a drug-dendrimer conjugate, and uses preclinical and mathematical models to determine the optimal release rate of the drug for maximal therapeutic index. The optimized candidate shows improved efficacy and tolerability compared to AZD4320 alone, enabling progression of this promising dual Bcl-2/Bcl-x(L) inhibitor into clinical development.

COMMUNICATIONS BIOLOGY (2021)

添加到收藏夹

Review Hematology

Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation

Emil Kumar et al.

Summary: Follicular lymphoma (FL) is a heterogeneous disease with increasing recognition of recurrent genetic alterations in epigenetic regulators as a pivotal hallmark. Studies are beginning to uncover the convergence between genetics, epigenetics, and the tumor microenvironment, emphasizing the need to integrate biology with therapeutics for optimal patient care.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Education, Scientific Disciplines

Follicular lymphoma: is there an optimal way to define risk?

Carla Casulo

Summary: Follicular lymphoma (FL) is characterized by a long natural history and typically indolent behavior. A plethora of prognostic factors, combining clinical, biological, and genetic data, are available to determine patient prognosis and aid in treatment strategy development. The rapid pace of advances in FL research poses challenges in prioritizing and implementing these factors in clinical practice, but a comprehensive understanding of existing prognostic markers can help optimize their clinical utility and explore opportunities for risk intervention at diagnosis and recurrence.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)

添加到收藏夹

Review Hematology

Past, present and future of prognostic scores in follicular lymphoma

Pablo Mozas et al.

Summary: Prognostic indexes are crucial for the long-term outcomes of FL patients, but challenges remain in determining their accuracy and clinical significance. External validity factors include characteristics of the study population, treatment intervention, and study design. Recent studies have incorporated genomic and imaging data to improve prognostic accuracy for the heterogeneous FL population.

BLOOD REVIEWS (2021)

添加到收藏夹

Article Oncology

High-risk follicular lymphoma: Treatment options

Brad Kahl

Summary: Follicular lymphoma is the most common indolent non-Hodgkin lymphoma in the Western hemisphere, with rituximab showing favorable effects on overall survival and progression-free survival. Obinutuzumab has shown better results in some studies compared to rituximab, but requires more drug. Although chemotherapy strategies have evolved, there are still unmet needs in identifying high-risk patients, developing predictive biomarkers, and reducing the risk of transformation.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era

Arushi Khurana et al.

Summary: Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over watch and wait (W/W) strategy. The likelihood of treatment initiation in the next 5 years for FL patients on the W/W strategy for 5 years was 12% compared to 43% at diagnosis, showing no significant association with the presence of popular treatment criteria at diagnosis. Further research is needed to identify biological differences in patients with early vs. late or no progression to understand outcomes in W/W patients.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Article Hematology

M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy

Sandra Lockmer et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Oncology

Epidemiology of Follicular Lymphoma

James R. Cerhan

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)

添加到收藏夹

Review Hematology

How to manage early-stage follicular lymphoma

Emanuele Cencini et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

添加到收藏夹

Meeting Abstract Hematology

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic et al.

BLOOD (2019)

添加到收藏夹

Article Medicine, General & Internal

Follicular lymphoma

Antonino Carbone et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

添加到收藏夹

Article Hematology

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico et al.

LANCET HAEMATOLOGY (2018)

添加到收藏夹

Review Oncology

Past, Present, and Future of Rituximab-The world's First Oncology Monoclonal Antibody Therapy

Timothy M. Pierpont et al.

FRONTIERS IN ONCOLOGY (2018)

添加到收藏夹

Review Oncology

From genetics to the clinic: a translational perspective on follicular lymphoma

Sarah Huet et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Article Education, Scientific Disciplines

Where to start? Upfront therapy for follicular lymphoma in 2018

John P. Leonard et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)

添加到收藏夹

Article Public, Environmental & Occupational Health

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study

James R. Cerhan et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)

添加到收藏夹

Article Hematology

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab

Sarah Huet et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

添加到收藏夹

Article Hematology

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Matthew J. Maurer et al.

AMERICAN JOURNAL OF HEMATOLOGY (2016)

添加到收藏夹

Review Hematology

Follicular lymphoma: evolving therapeutic strategies

Brad S. Kahl et al.

BLOOD (2016)

添加到收藏夹

Review Hematology

Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

Javeed Iqbal et al.

BLOOD REVIEWS (2016)

添加到收藏夹

Article Medicine, General & Internal

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study

Robert Kridel et al.

PLOS MEDICINE (2016)

添加到收藏夹

Review Immunology

Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity

Rafael Casellas et al.

NATURE REVIEWS IMMUNOLOGY (2016)

添加到收藏夹

Article Oncology

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Review Immunology

AID targeting: old mysteries and new challenges

Vivek Chandra et al.

TRENDS IN IMMUNOLOGY (2015)

添加到收藏夹

Article Hematology

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Cristina Correia et al.

BLOOD (2015)

添加到收藏夹

Article Biochemical Research Methods

The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation

Jean-Pierre A. Kocher et al.

BIOINFORMATICS (2014)

添加到收藏夹

Article Oncology

Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

Brad S. Kahl et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna et al.

LANCET ONCOLOGY (2014)

添加到收藏夹

Editorial Material Oncology

Follicular lymphoma: watch and wait is watch and worry

Stephen M. Ansell

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Genetics & Heredity

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

Jessica Okosun et al.

NATURE GENETICS (2014)

添加到收藏夹

Article Cell Biology

Genetics of Follicular Lymphoma Transformation

Laura Pasqualucci et al.

CELL REPORTS (2014)

添加到收藏夹

Article Oncology

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

Brian K. Link et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Multidisciplinary Sciences

An integrated map of genetic variation from 1,092 human genomes

David M. Altshuler et al.

NATURE (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Btrim: A fast, lightweight adapter and quality trimming program for next-generation sequencing technologies

Yong Kong

GENOMICS (2011)

添加到收藏夹

Article Biochemical Research Methods

BEDTools: a flexible suite of utilities for comparing genomic features

Aaron R. Quinlan et al.

BIOINFORMATICS (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Aaron McKenna et al.

GENOME RESEARCH (2010)

添加到收藏夹

Article Oncology

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Grzegorz S. Nowakowski et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Multidisciplinary Sciences

A map of human genome variation from population-scale sequencing

David Altshuler et al.

NATURE (2010)

添加到收藏夹

Article Genetics & Heredity

Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants

Yingrui Li et al.

NATURE GENETICS (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells

Jonna Eeva et al.

APOPTOSIS (2009)

添加到收藏夹

Article Biochemical Research Methods

Fast and accurate short read alignment with Burrows-Wheeler transform

Heng Li et al.

BIOINFORMATICS (2009)

添加到收藏夹

Article Oncology

Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma

Anna Margret Halldorsdottir et al.

LEUKEMIA RESEARCH (2008)

添加到收藏夹

Article Hematology

Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma

C Bödör et al.

BRITISH JOURNAL OF HAEMATOLOGY (2005)

添加到收藏夹

Article Oncology

Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL

MS Hardianti et al.

LEUKEMIA (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.